You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Weber J, Grob J, Margolin KA, et al
A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
Journal for ImmunoTherapy of Cancer 2015;3:P166. doi: 10.1186/2051-1426-3-S2-P166